Analyst Conference Summary

biotechnology

conference date: July 30, 2026 @ 5:30 AM Pacific Time
for quarter ending: June 30, 2026 (second quarter, Q2)

Forward-looking statements

Overview:

Basic data (GAAP):

Revenue was $ billion, up % sequentially from $1.17 billion, and up % from $ million year-earlier.

Net income was $ million, up % sequentially from $206 million, and up from negative $ million year-earlier.

Diluted EPS was $, up % sequentially from $1.51, and up from negative $ year-earlier.

Guidance:

Conference Highlights:

Yvonne Greenstreet, CEO of Alnylam, said: ""

In the first half of 2026 Alnylam expects to complete enrollment in the Phase 2 mivelsiran trial for cerebral amyloid angiopathy. Plans to start a Phase trial of mivelsiran for Alzheimer's. Also plans to start a phase 2 trial for Alzheimer's.

Net revenue from collaborations was $ million, down from $ million year-earlier. Royalty revenue was $ million, up from $ million year-earlier.

Non-GAAP net income $ million, up % sequentially from $273 million, and up from $ million year-earlier. EPS diluted $, up % sequentially from $1.99, and up from $ year-earlier.

Cash and equivalents balance at the end of the quarter was $ billion, up sequentially from $3.01 billion. Net cash provided by operating activities was $ million.

See also Alnylam pipeline. In early 2026 had 25 clinical programs including many in late stages.

Operating expenses of $ million consisted of: $ million for cost of goods sold; $ million for research and development; and $ million for general and administrative expense; $ million cost of collaboration. Operating income $ million. Interest & other expense $ million. $ million income tax.

Q&A Selective Summary:

OpenIcon Alnylam page

OpenIcon Analyst Conference Summaries Main Page

Search

More Analyst Conference Pages: